Omnicell, Inc. (OMCL)
| Market Cap | 2.03B |
| Revenue (ttm) | 1.23B |
| Net Income (ttm) | 20.43M |
| Shares Out | 45.48M |
| EPS (ttm) | 0.44 |
| PE Ratio | 102.01 |
| Forward PE | 23.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,509,502 |
| Open | 45.13 |
| Previous Close | 37.63 |
| Day's Range | 43.07 - 46.89 |
| 52-Week Range | 22.66 - 55.00 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 54.17 (+21.08%) |
| Earnings Date | Apr 28, 2026 |
About OMCL
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-hous... [Read more]
Financial Performance
In 2025, Omnicell's revenue was $1.18 billion, an increase of 6.53% compared to the previous year's $1.11 billion. Earnings were $2.05 million, a decrease of -83.62%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for OMCL stock is "Buy." The 12-month stock price target is $54.17, which is an increase of 21.08% from the latest price.
News
Omnicell Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded guidance with 15% revenue growth, improved margins, and strong recurring revenue momentum. Full-year guidance was raised for EBITDA and EPS, supported by robust demand for new platforms and disciplined cost management.
Omnicell Announces First Quarter 2026 Financial Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces First Quarter 2026 Financial Results.
Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026.
Omnicell Earnings Call Transcript: Q4 2025
Delivered strong Q4 and FY 2025 results, exceeding guidance for revenue, bookings, and ARR. Launched Titan XT and expanded OmniSphere, driving robust demand and competitive wins. FY 2026 guidance anticipates continued growth, with investments in innovation, cloud, and sales force.
Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results.
Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026.
Omnicell Transcript: Investor Update
Titan XT, a new cloud-based enterprise platform, launches with advanced analytics, AI, and security for large health systems. Hardware shipments begin in late 2026, with modest initial revenue and a $2.5 billion market opportunity. Recurring revenue will grow through service and software subscriptions.
Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management
FORT WORTH, Texas--(BUSINESS WIRE)--Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management.
Omnicell Transcript: Piper Sandler 37th Annual Healthcare Conference
Leadership changes and new enterprise solutions are driving a shift to flexible, recurring revenue models. Product innovation, including cloud-based platforms and workflow enhancements, is accelerating growth and margin expansion, with strong execution offsetting tariff and policy headwinds.
Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show.
Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference.
Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies.
Omnicell Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 10% year-over-year to $311 million, with non-GAAP EBITDA and EPS exceeding guidance. Strong demand for point of care and specialty pharmacy solutions drove results, while tariff impacts and slower SaaS growth in EnlivenHealth were noted. Full-year guidance was raised.
Omnicell Announces Third Quarter 2025 Financial Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Third Quarter 2025 Financial Results.
Omnicell to Release Third Quarter 2025 Financial Results on October 30, 2025
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2025 Financial Results on October 30, 2025.
Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer.
Omnicell Earnings Call Transcript: Q2 2025
Q2 2025 saw 5% revenue growth year-over-year and strong sequential gains, with all major product categories contributing. Full-year guidance for revenue, non-GAAP EBITDA, and EPS was raised, and recurring revenue now represents about half of the business. Tariff headwinds persist but are being mitigated.
Omnicell Announces Second Quarter 2025 Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Second Quarter 2025 Results.
Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025.
Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program.
Omnicell Announces New Products for Perioperative and Clinic Settings
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces New Products for Perioperative and Clinic Settings.
Omnicell Opens New Innovation Lab in Austin, Texas
AUSTIN, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced the opening of its I...
Omnicell Earnings Call Transcript: Q1 2025
First quarter 2025 saw strong revenue and recurring growth, with robust demand for medication management solutions and key wins in specialty and outpatient pharmacy. Tariffs on China-sourced components are expected to impact 2025 EBITDA by $40M, prompting supply chain mitigation and revised guidance.
Omnicell Announces First Quarter 2025 Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces First Quarter 2025 Results.
Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer.